The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert following the declaration of over 100 medications as Not of Standard Quality (NSQ) by India’s Central Drugs Standard Control Organization (CDSCO).
According to information received by NAFDAC, these drugs failed quality control tests conducted on samples collected from distribution and sales points across India.
The affected medications were manufactured by 17 pharmaceutical companies, some of which have subsidiaries, business partners, or product distributions in Nigeria.
The companies identified in the CDSCO report include:
Abaris Healthcare Pvt Ltd
Alencure Biotech Pvt Ltd
Eurolife Healthcare Pvt Ltd
Health Biotech Ltd
HIGGS Healthcare
Karnataka Antibiotics & Pharmaceuticals Ltd (KAPL)
Laborate Pharmaceuticals India Ltd
Legend Industries
Martins & Brown Biosciences Pvt Ltd
Mascot Health Series Pvt Ltd
Micron Pharmaceutical
Orison Pharma International
Rivpra Formulation Pvt Ltd
Sai Parenterals Ltd
Symbiosis Pharmaceuticals Pvt Ltd
Syncom Formulations (India) Ltd
Zee Laboratories Ltd
NAFDAC has urged healthcare professionals, pharmacists, and consumers to exercise caution and vigilance. Suspected cases of substandard or falsified medicines should be reported to the nearest NAFDAC office.
The agency emphasized its commitment to safeguarding public health and warned that it is actively investigating the local presence of these products.
